Huynh Thao, Montigny Martine, Iftikhar Umair, Gagnon Roxanne, Eisenberg Mark, Lauzon Claude, Mansour Samer, Rinfret Stephane, Afilalo Marc, Nguyen Michel, Kouz Simon, Déry Jean-Pierre, Harvey Richard, De LaRocheliere Robert, Cantin Bernard, Schampaert Eerick, Tardif Jean-Claude
McGill Health University Center, Montreal, Canada.
Cité de la Santé de Laval, Laval, Canada.
Am J Cardiol. 2018 Apr 15;121(8):897-902. doi: 10.1016/j.amjcard.2017.12.037. Epub 2018 Jan 31.
The characteristics and predictors of long-term recurrent ischemic cardiovascular events (RICEs) after myocardial infarction with ST-segment elevation (STEMI) have not yet been clarified. We aimed to characterize the 10-year incidence, types, and predictors of RICE. We obtained 10-year follow-up of STEMI survivors at 17 Quebec hospitals in Canada (the AMI-QUEBEC Study) in 2003. There were 858 patients; mean age was 60 years and 73% were male. The majority of patients receive reperfusion therapy; 53.3% and 39.2% of patients received primary percutaneous coronary intervention (PCI) and fibrinolytic therapy, respectively. Seventy-five percent of patients underwent in-hospital PCI (elective, rescue, and primary). At 10 years, 42% of patients suffered a RICE, with most RICEs (88%) caused by recurrent cardiac ischemia. The risk of RICE was the highest during the first year (23.5 per patient-year). At 10 years, the all-cause mortality was 19.3%, with 1/3 of deaths being RICE-related. Previous cardiovascular event, heart failure during the index STEMI hospitalization, discharge prescription of calcium blocker increased the risk of RICE by almost twofold. Each point increase in TIMI (Thrombolysis In Myocardial Infarction) score augmented the risk of RICE by 6%, whereas discharge prescription of dual antiplatelets reduced the risk of RICE by 23%. Our findings suggested that survivors of STEMI remain at high long-term risk of RICE despite high rate of reperfusion therapy and in-hospital PCI. Patients with previous cardiovascular event, in-hospital heart failure, and high TIMI score were particularly susceptible to RICE. Future studies are needed to confirm the impacts of calcium blocker and dual antiplatelets on long-term risk of RICE.
ST段抬高型心肌梗死(STEMI)后长期复发性缺血性心血管事件(RICEs)的特征和预测因素尚未明确。我们旨在描述RICE的10年发病率、类型及预测因素。2003年,我们对加拿大魁北克省17家医院的STEMI幸存者进行了10年随访(AMI-QUEBEC研究)。共有858例患者,平均年龄60岁,73%为男性。大多数患者接受了再灌注治疗,分别有53.3%和39.2%的患者接受了直接经皮冠状动脉介入治疗(PCI)和溶栓治疗。75%的患者接受了住院PCI(选择性、补救性和直接PCI)。10年后,42%的患者发生了RICE,大多数RICE(88%)由复发性心肌缺血引起。RICE风险在第一年最高(每患者年23.5例)。10年后,全因死亡率为19.3%,其中1/3的死亡与RICE相关。既往心血管事件、首次STEMI住院期间发生心力衰竭、出院时开具钙通道阻滞剂会使RICE风险增加近两倍。心肌梗死溶栓治疗(TIMI)评分每增加1分,RICE风险增加6%,而出院时开具双联抗血小板药物可使RICE风险降低23%。我们的研究结果表明,尽管再灌注治疗和住院PCI的比例很高,但STEMI幸存者仍长期面临较高的RICE风险。既往有心血管事件、住院期间发生心力衰竭及TIMI评分高的患者尤其易发生RICE。未来需要进一步研究以证实钙通道阻滞剂和双联抗血小板药物对RICE长期风险的影响。